Global Cystic Fibrosis Therapeutics Market Forecast 2020-2028

KEY FINDINGS

The global cystic fibrosis therapeutics market is anticipated to grow at a rate of 10.04% during the estimated period of 2020-2028. A rise in incidences of cystic fibrosis across the globe, an increase in medications against cystic fibrosis, and a hike in R&D investments towards the development of drugs to treat cystic fibrosis are boosting the market.

MARKET INSIGHTS

Cystic fibrosis is a disease that is inherited and mainly affects the lungs and other body parts like the kidney, pancreas, and liver. In cystic fibrosis, thick and sticky mucus is produced by the body that may block the lungs and obstruct the pancreas. There is no cure for the fatal disease, but taking proper medication and nutrition to reduce excess mucus produced in the lungs and kidney can help in increasing the patient's lifespan. The disease is most prevalent in newborns, and has led the researchers towards the development of advanced therapeutics, which may increase the life span of the patients. However, the high costs involved in cystic fibrosis treatment and the introduction of generic drugs impede the market growth. At the same time, the growth of the healthcare industry in developing economies is expected to create profitable opportunities in the future.

REGIONAL INSIGHTS

The global cystic fibrosis therapeutics market is geographically analyzed based on markets situated in North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of Europe holds the largest market share in terms of revenue, and continues the trend by the end of the forecast period. This is attributed to the presence of key players investing largely in the development of new technologies. The market region of Europe is predicted to be the fastest-growing market in terms of revenue. The major factor driving the growth is the surge in incidences of cystic fibrosis in the region.

COMPETITIVE INSIGHTS

Abbott Laboratories, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd, Pharmaxis Ltd, Novartis International AG, etc. are some of the leading companies registering their presence in the global market.

Our report offerings include:

• Explore key findings of the overall market

• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

• Market Segmentation cater to a thorough assessment of key segments with their market estimations

• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

• 1.1. STUDY OBJECTIVES
• 1.2. SCOPE OF STUDY
• 1.3. METHODOLOGY
• 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

• 2.1. MARKET SIZE & ESTIMATES
• 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

• 3.1. MARKET DEFINITION
• 3.2. KEY DRIVERS
  • 3.2.1. ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
  • 3.2.2. INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
  • 3.2.3. RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
• 3.3. KEY RESTRAINTS
  • 3.3.1. STRINGENT REGULATION
  • 3.3.2. LOW AWARENESS AMONG DEVELOPING ECONOMIES

4. KEY ANALYTICS

• 4.1. PORTER'S FIVE FORCE ANALYSIS
  • 4.1.1. THREAT OF NEW ENTRY
  • 4.1.2. THREAT OF SUBSTITUTION
  • 4.1.3. BUYER'S POWER
  • 4.1.4. SUPPLIER'S POWER
  • 4.1.5. COMPETITIVE RIVALRY
• 4.2. PESTEL ANALYSIS
• 4.3. OPPORTUNITY MATRIX
• 4.4. VENDOR LANDSCAPE
• 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY ROUTE OF ADMINISTRATION

• 5.1. INHALE
• 5.2. ORAL

6. MARKET BY DRUG CLASS

• 6.1. CFTR MODULATORS
• 6.2. BRONCHODILATORS
• 6.3. MUCOLYTIC
• 6.4. PANCREATIC ENZYME SUPPLEMENTS

7. GEOGRAPHICAL ANALYSIS

• 7.1. NORTH AMERICA
  • 7.1.1. THE UNITED STATES
  • 7.1.2. CANADA
• 7.2. EUROPE
  • 7.2.1. THE UNITED KINGDOM
  • 7.2.2. FRANCE
  • 7.2.3. GERMANY
  • 7.2.4. ITALY
  • 7.2.5. RUSSIA
  • 7.2.6. BELGIUM
  • 7.2.7. POLAND
  • 7.2.8. REST OF EUROPE
• 7.3. ASIA PACIFIC
  • 7.3.1. CHINA
  • 7.3.2. JAPAN
  • 7.3.3. INDIA
  • 7.3.4. AUSTRALIA & NEW ZEALAND
  • 7.3.5. SOUTH KOREA
  • 7.3.6. THAILAND
  • 7.3.7. INDONESIA
  • 7.3.8. VIETNAM
  • 7.3.9. REST OF ASIA PACIFIC
• 7.4. REST OF WORLD
  • 7.4.1. LATIN AMERICA
  • 7.4.2. MIDDLE EAST & AFRICA

8. COMPANY PROFILES

• 8.1. ABBOTT LABORATORIES
• 8.2. ABBVIE INC
• 8.3. AGILENT TECHNOLOGIES INC
• 8.4. ALLERGAN PLC
• 8.5. F. HOFFMANN-LA ROCHE
• 8.6. GILEAD SCIENCES INC
• 8.7. GLAXOSMITHKLINE PLC
• 8.8. JOHNSON & JOHNSON
• 8.9. MYLAN N.V
• 8.10. NOVARTIS AG
• 8.11. PERKINELMER
• 8.12. PFIZER INC
• 8.13. PHARMAXIS LTD
• 8.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
• 8.15. VERTEX PHARMACEUTICALS INCORPORATED

LIST OF TABLES

• TABLE 1: MARKET SNAPSHOT - VETERINARY VACCINE
• TABLE 2: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 3: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 4: GLOBAL INHALE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 5: GLOBAL INHALE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 6: GLOBAL ORAL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 7: GLOBAL ORAL MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 8: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 9: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 10: GLOBAL CFTR MODULATORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME
• TABLE 12: GLOBAL CFTR MODULATORS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 13: GLOBAL BRONCHODILATORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME
• TABLE 15: GLOBAL BRONCHODILATORS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 16: GLOBAL MUCOLYTIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME
• TABLE 18: GLOBAL MUCOLYTIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 19: GLOBAL PANCREATIC ENZYME SUPPLEMENTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 20: GLOBAL PANCREATIC ENZYME SUPPLEMENTS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 21: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 22: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 23: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 24: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 25: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 26: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 27: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 28: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
• TABLE 29: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
• TABLE 30: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

• FIGURE 1: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 2: OPPORTUNITY MATRIX
• FIGURE 3: VENDOR LANDSCAPE
• FIGURE 4: KEY INVESTMENT INSIGHTS
• FIGURE 5: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019
• FIGURE 6: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)
• FIGURE 7: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)
• FIGURE 8: GLOBAL CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019
• FIGURE 9: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)
• FIGURE 10: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)
• FIGURE 11: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)
• FIGURE 12: GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)
• FIGURE 13: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
• FIGURE 14: THE UNITED STATES CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 15: CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 16: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
• FIGURE 17: THE UNITED KINGDOM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 18: FRANCE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 19: GERMANY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 20: ITALY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 21: RUSSIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 22: BELGIUM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 23: POLAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 24: REST OF EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 25: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
• FIGURE 26: CHINA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
• FIGURE 27: JAPAN CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
• FIGURE 28: INDIA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
• FIGURE 29: AUSTRALIA & NEW ZEALAND CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)
• FIGURE 30: SOUTH KOREA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 31: THAILAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 32: INDONESIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 33: VIETNAM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 34: REST OF ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 35: REST OF WORLD CYSTIC FIBROSIS THERAPEUTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
• FIGURE 36: LATIN AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
• FIGURE 37: MIDDLE EAST & AFRICA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)